SLC5A2 and type 2 diabetes mellitus: The only cardiovascular outcomes trial of SGLT-2 inhibitors to date, the EMPA-REG OUTCOME trial, showed that empagliflozin use was associated with a reduction in the primary composite endpoint of cardiovascular mortality, non-fatal MI, or non-fatal stroke compared with placebo in T2D patients [48].